Zhang Y, Trissel L A
University of Texas M. D. Anderson Cancer Center, Houston 77030, USA.
J Am Pharm Assoc (Wash). 1999 Mar-Apr;39(2):146-50. doi: 10.1016/s1086-5802(16)30489-2.
To evaluate the physical and chemical stability of etoposide phosphate solutions over 7 days at 32 degrees C and 31 days at 4 degrees C and 23 degrees C: (1) at etoposide concentrations of 0.1 and 10 mg/mL as phosphate in 0.9% sodium chloride injection and 5% dextrose injection and (2) at etoposide concentrations of 10 and 20 mg/mL as phosphate in bacteriostatic water for injection packaged in plastic syringes.
Test samples of etoposide phosphate were prepared in polyvinyl chloride (PVC) bags of the two infusion solutions at etoposide concentrations of 0.1 and 10 mg/mL as phosphate. Additional test samples were prepared in bacteriostatic water for injection containing benzyl alcohol 0.9% at etoposide concentrations of 10 and 20 mg/mL as phosphate and were packaged in 5 mL plastic syringes. Evaluations for physical and chemical stability were performed initially; after 1 and 7 days of storage at 32 degrees C; and after 1, 7, 14, and 31 days of storage at 4 degrees C and 23 degrees C. Physical stability was assessed using visual observation in normal light and using a high-intensity monodirectional light beam. Turbidity and particle content were measured electronically. Chemical stability of the drug was evaluated by using a stability-indicating high-performance liquid chromatographic (HPLC) analytic technique.
All samples were physically stable throughout the study. Little or no change in particulate burden and haze level were found. In the intravenous infusion solutions, little or no loss of etoposide phosphate occurred in any of the samples throughout the study period. The 10 and 20 mg/mL samples in bacteriostatic water for injection repackaged in syringes were also stable throughout the study, exhibiting a maximum of 6% or 7% loss after 31 days of storage at 23 degrees C and less than 4% in 31 days at 4 degrees C.
Etoposide phosphate prepared as intravenous admixtures of etoposide 0.1 and 10 mg/mL as phosphate in 5% dextrose injection and 0.9% sodium chloride injection in PVC bags and as etoposide 10 and 20 mg/mL as phosphate in bacteriostatic water for injection packaged in plastic syringes is physically and chemically stable for at least 7 days at 32 degrees C and 31 days at 4 degrees C and 23 degrees C. This new water-soluble phosphate-ester of etoposide formulation solves the precipitation problems associated with the old organic solvent and surfactant-based formulation.
评估磷酸依托泊苷溶液在32℃下7天以及4℃和23℃下31天的物理和化学稳定性:(1)在0.9%氯化钠注射液和5%葡萄糖注射液中,磷酸依托泊苷浓度为0.1和10mg/mL;(2)在塑料注射器包装的注射用抑菌水中,磷酸依托泊苷浓度为10和20mg/mL。
在两种输液溶液的聚氯乙烯(PVC)袋中制备磷酸依托泊苷测试样品,磷酸依托泊苷浓度为0.1和10mg/mL。另外,在含0.9%苯甲醇的注射用抑菌水中制备测试样品,磷酸依托泊苷浓度为10和20mg/mL,并包装在5mL塑料注射器中。最初进行物理和化学稳定性评估;在32℃储存1天和7天后;以及在4℃和23℃储存1天、7天、14天和31天后。通过在正常光线下目视观察和使用高强度单向光束评估物理稳定性。用电学方法测量浊度和颗粒含量。通过使用稳定性指示高效液相色谱(HPLC)分析技术评估药物的化学稳定性。
在整个研究过程中,所有样品的物理性质均稳定。颗粒负荷和雾度水平几乎没有变化或没有变化。在静脉输液溶液中,在整个研究期间,任何样品中磷酸依托泊苷的损失很少或没有损失。重新包装在注射器中的注射用抑菌水中10和20mg/mL样品在整个研究过程中也很稳定,在23℃储存31天后最大损失为6%或7%,在4℃储存31天后损失小于4%。
以静脉内混合制剂形式制备的磷酸依托泊苷,即磷酸依托泊苷0.1和10mg/mL在PVC袋中的5%葡萄糖注射液和0.9%氯化钠注射液中,以及磷酸依托泊苷10和20mg/mL在塑料注射器包装的注射用抑菌水中,在32℃下至少7天以及在4℃和23℃下31天物理和化学性质稳定。这种新的依托泊苷水溶性磷酸酯制剂解决了与旧的基于有机溶剂和表面活性剂的制剂相关的沉淀问题。